SIPA1L1: A Potential Drug Target and Biomarker (G26037)

Target Name: SIPA1L1

NCBI ID: G26037

SIPA1L1

SIPA1L1: A Potential Drug Target and Biomarker

SIPA1L1 (H_DJ1140G11.1), a protein found in various tissues throughout the body, has been identified as a potential drug target or biomarker. Its unique structure and various functions in different cellular processes make it an attractive target for scientists and doctors.

SIPA1L1 is a protein that belongs to the SIPA family, which is known for their role in various cellular processes, including cell signaling, DNA replication, and chromatin remodeling. SIPA1L1 is a 194-kDa protein that consists of 216 amino acids. It has a unique structure, with a clear N-terminus, a long N-calcium-calcium-dependent extracellular domain, and a C-terminus that is involved in protein-protein interactions.

One of the most significant features of SIPA1L1 is its role in the regulation of DNA replication. SIPA1L1 has been shown to play a crucial role in the replication of DNA in various cell types, including HeLa cells, HeLa-derived sarcoma cells, and human T cells. It has been shown to interact with the proteininker DFN, which is involved in the initiation of DNA replication.

In addition to its role in DNA replication, SIPA1L1 has also been shown to play a role in cell signaling. SIPA1L1 has been shown to interact with the protein Pyh, which is involved in the regulation of cell signaling pathways, including the TGF-β pathway . This interaction between SIPA1L1 and Pyh has been shown to play a role in the regulation of cellular processes, including cell growth, differentiation, and inflammation.

SIPA1L1 has also been shown to have neuroprotective properties. SIPA1L1 has been shown to protect against neurotoxicity in various cellular models, including the neurotoxicity caused by the neurotransmitter glutamate. This neuroprotective effect of SIPA1L1 is mediated by its interaction with the protein Bcl-2, which is involved in the regulation of cell survival and neurotransmitter release.

SIPA1L1 has also been shown to have potential as a biomarker. Its unique structure and various functions make it an attractive target for diagnostic tests. For example, SIPA1L1 has been shown to be expressed in various tissues and cell types, including brain, heart, liver , and muscle. This makes it a potential biomarker for a variety of diseases, including neurodegenerative diseases, cardiovascular diseases, and diseases associated with muscle loss.

In conclusion, SIPA1L1 is a protein that has a unique structure and functions that make it an attractive target for drug development and biomarker research. Its role in the regulation of DNA replication, cell signaling, and neuroprotection makes it a potential drug target for a variety of diseases. Further research is needed to fully understand the unique properties of SIPA1L1 and its potential as a drug target and biomarker.

Protein Name: Signal Induced Proliferation Associated 1 Like 1

Functions: Stimulates the GTPase activity of RAP2A. Promotes reorganization of the actin cytoskeleton and recruits DLG4 to F-actin. Contributes to the regulation of dendritic spine morphogenesis (By similarity)

The "SIPA1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIPA1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets